Moderna, Inc. (NASDAQ:MRNA) Stock Has Consensus Target Price of $101.45 According to Analysts

Posted by Brenda Bartman on Oct 23rd, 2026

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) has earned a consensus recommendation of “Hold” from the twenty-five ratings firms that are presently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $103.95.

A number of research analysts have recently issued reports on the stock. Brookline Capital Markets restated a “buy” rating on shares of Moderna in a research report on Wednesday, August 19th. Berenberg Bank upped their price objective on shares of Moderna from $45.00 to $100.00 and gave the company a “hold” rating in a research note on Friday, September 11th. Rothschild & Co Redburn cut shares of Moderna from a “neutral” rating to a “sell” rating and upped their price target for the company from $40.00 to $81.00 in a research report on Thursday, September 3rd. JPMorgan Chase & Co. upped their price target on shares of Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a research report on Friday, August 21st. Finally, Deutsche Bank Aktiengesellschaft began coverage on Moderna in a report on Friday, August 28th. They set a “hold” rating and a $125.00 price target for the company.

Get Our Latest Stock Analysis on MRNA

Moderna Stock Down 17.6%

Shares of MRNA opened at $202.63 on Tuesday. The business has a 50-day moving average of $170.05 and a 200-day moving average of $96.24. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. Moderna has a 1 year low of $22.28 and a 1 year high of $254.48.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.03) by $0.06. The business had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The firm’s revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the business posted ($2.13) earnings per share. Equities research analysts anticipate that Moderna will post -6.11 EPS for the current fiscal year.

Key Moderna News

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Detailed Phase 3 INTerpath-001 results showed positive recurrence-free survival and distant metastasis-free survival for intismeran autogene, Moderna’s individualized mRNA cancer vaccine used with Merck’s Keytruda. The results support the program’s potential to become a major non-COVID growth driver. Merck and Moderna INTerpath-001 Results
Positive Sentiment: Moderna advanced its mRNA bird-flu vaccine into a late-stage trial, expanding its pipeline into pandemic influenza. The company also said it plans to reserve 20% of related manufacturing capacity for low- and middle-income countries if the vaccine is approved. Moderna Starts Late-Stage Bird Flu Trial
Neutral Sentiment: Moderna’s addition to the Nasdaq-100 has increased institutional visibility and contributed to recent momentum, but the sharp run-up also left the stock vulnerable to profit-taking when new clinical information emerged. Moderna Nasdaq-100 Inclusion
Negative Sentiment: Partial melanoma-vaccine data circulated online before Moderna’s scheduled ESMO presentation. Although the findings appeared clinically meaningful, investors viewed the leak as an information-quality and timing problem, while the lack of a fresh surprise raised “sell-the-news” concerns. Trading was temporarily halted because of volatility. Reuters Moderna Cancer Vaccine Data Report
Negative Sentiment: TD Cowen raised its price target to $90 but maintained a Hold rating, leaving substantial downside relative to the stock’s recent trading level and reinforcing valuation concerns. TD Cowen Moderna Price Target
Negative Sentiment: A law firm announced an investigation into potential securities-law violations related to Moderna’s October 22 disclosure. The announcement does not establish wrongdoing, but it adds headline and legal risk following the abrupt decline. Moderna Securities Investigation

Insider Buying and Selling at Moderna

In related news, President Stephen Hoge sold 40,294 shares of the stock in a transaction on Monday, September 14th. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the transaction, the president directly owned 1,525,858 shares of the company’s stock, valued at $219,921,913.54. This represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Jamey Mock sold 34,836 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. This trade represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Moderna

A number of large investors have recently modified their holdings of MRNA. BlackRock Inc. bought a new stake in shares of Moderna during the second quarter worth about $2,142,877,000. Theleme Partners LLP purchased a new stake in shares of Moderna in the second quarter worth approximately $564,272,000. Merck & Co. Inc. purchased a new stake in shares of Moderna in the second quarter worth approximately $161,642,545. Bamco Inc. NY bought a new position in shares of Moderna in the second quarter valued at approximately $139,317,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Moderna in the second quarter valued at approximately $119,168,000. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

(Get Free Report)

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.